4.6 Article

Glucose Effectiveness: The Mouse Trap in the Development of Novel beta-Cell Replacement Therapies

Journal

TRANSPLANTATION
Volume 100, Issue 1, Pages 111-115

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000000900

Keywords

-

Funding

  1. Swedish Medical Research Council [K2011-65X-12219-15-6, K2015-54X-12219-19-4]
  2. Nordic Insulin Fund
  3. EFSD/Novo Nordisk Foundation
  4. Ernfors Family Fund
  5. Barn Diabetes Fonden
  6. Swedish Diabetes Association
  7. DiabetesWellness foundation
  8. EUFP7-HumEn [HEALTH-F4-2013-602889]
  9. Juvenile Diabetes Foundation International
  10. Novo Nordisk Fonden [NNF14OC0010935, NNF16OC0021334] Funding Source: researchfish

Ask authors/readers for more resources

Background Cure of diabetes and normalization of glucose disposal during intravenous glucose tolerance tests (IVGTT) remains critical for stringent evaluation of novel replacement therapies in type 1 diabetes. Glucose disposal during an IVGTT depends on a complex interaction of both insulin-dependent and -independent mechanisms. Glucose effectiveness, that is, the function of glucose per se, independent of insulin, to stimulate its uptake and suppress endogenous glucose production is less recognized. Methods To unravel the relative importance of these pathways, rats were injected with streptozotocin to induce diabetes and implanted subcutaneously with slow-release devices of insulin. Results These animals demonstrated rapid normalization of blood glucose and perfectly normal glucose disposal during an IVGTT with no differences when compared with nondiabetic controls even though no active c-peptide secretion was detected in plasma and almost no remaining insulin-producing cells were present in the pancreas. Conclusions The present study highlights that glucose is the predominant mediator of its own disposal in rodents having only basal and nonglucose-regulated plasma insulin levels. The herein presented results calls for a reassessment how results obtained in the most commonly used experimental models should be interpreted in the development of future replacement therapies in type 1 diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available